Nektar Therapeutics Prices Upsized $325M Public Offering to Fund Phase 3 Clinical Trials

summarizeSummary

Nektar Therapeutics finalized the pricing of an upsized $325 million public offering of common stock at $92.00 per share, aiming to fund critical Phase 3 clinical trials for rezpegaldesleukin following recent positive Phase 2b results.

check_boxKey Events

• Upsized Public Offering Priced

  Nektar Therapeutics priced an upsized public offering of 3,532,609 shares of common stock at $92.00 per share, raising gross proceeds of $325 million. This finalizes the terms of the offering initiated on April 20, 2026.

• Significant Capital Raise

  The company expects to receive approximately $305.1 million in net proceeds, which could increase to $350.9 million if the underwriters fully exercise their option to purchase an additional 529,891 shares.

• Funding for Phase 3 Trials

  Proceeds are intended for general corporate purposes, including research and development, clinical development (specifically Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata), and manufacturing costs.

• Dilution for New Investors

  New investors in this offering will experience an immediate dilution of $63.78 per share, reflecting the difference between the offering price and the pro forma as adjusted net tangible book value per share.

auto_awesomeAnalysis

Nektar Therapeutics has finalized the terms and pricing of its public offering, upsized to $325 million, selling 3,532,609 shares of common stock at $92.00 per share. This offering follows the preliminary announcement on April 20, 2026, and is strategically timed after the company reported positive Phase 2b clinical trial results for rezpegaldesleukin. The net proceeds, estimated at $305.1 million (or up to $350.9 million if underwriters exercise their option), are earmarked for general corporate purposes, including funding critical Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata. While the offering introduces dilution, raising substantial capital at near-market pricing (compared to today's $92.80 stock price) is a positive step for advancing its pipeline and extending its financial runway, especially given the high costs associated with late-stage clinical development in the life sciences sector.